Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs.
D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced* / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D014499:Uracil Mustard / Q000009:adverse effects / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
D000477:Alkylating Agents; D002699:Chlorambucil; D008558:Melphalan; D014499:Uracil Mustard